(Q38062466)

28 August 2017

1 reference

title

Treatment of cognitive impairment in multiple sclerosis: position paper (English)

1 reference

28 August 2017

0 references

cognitive dysfunction

1 reference

Dawn Langdon

2

0 references

Maria Pia Amato

object named as

Maria Pia Amato

1

0 references

Alan J. Thompson

object named as

Alan J Thompson

7

0 references

Giancarlo Comi

8

object named as

Giancarlo Comi

1 reference

28 August 2017

3

Xavier Montalban

1 reference

28 August 2017

Ralph H B Benedict

4

1 reference

28 August 2017

John DeLuca

5

1 reference

28 August 2017

Lauren B Krupp

6

1 reference

28 August 2017

publication date

23 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

260

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

1452-1468

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-012-6678-0

28 August 2017

exact match

0 references

cites work

Guidelines for neuropsychological research in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive impairment in early stages of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive function in radiologically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Association of MRI metrics and cognitive impairment in radiologically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Risk factors for and management of cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Reliable screening for neuropsychological impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Minimal neuropsychological assessment of MS patients: a consensus approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effects of neuropsychological treatment in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Methodological aspects of randomized controlled trials on cognitive interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The nature of memory impairments in multiple sclerosis: acquisition versus retrieval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Acquisition and storage deficits in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Self-generation to improve learning and memory of functional activities in persons with multiple sclerosis: meal preparation and managing finances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Self-generated learning in people with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Self-generated learning in people with multiple sclerosis: an extension of Chiaravalloti and DeLuca (2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

A functional application of the spacing effect to improve learning and memory in persons with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Examining the benefits of combining two learning strategies on recall of functional information in persons with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Increased cerebral activation after behavioral treatment for memory deficits in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Efficacy of a neuropsychological training programme for patients with multiple sclerosis -- a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Is speed of processing or working memory the primary information processing deficit in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Nonpharmacological cognitive interventions in aging and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The impact of speed of processing training on cognitive and everyday functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Computer assisted retraining of attentional impairments in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

An investigation of the differential effect of self-generation to improve learning and memory in multiple sclerosis and traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive strategies application of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

[Cognitive rehabilitation in multiple sclerosis: preliminary results and presentation of a new program, PROCOG-SEP].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Self-generation as a means of maximizing learning in multiple sclerosis: an application of the generation effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Retrieval practice improves memory in multiple sclerosis: clinical application of the testing effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Information processing efficiency in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

On the nature of memory disturbance in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

L-amphetamine improves memory in MS patients with objective memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Modafinil effects in multiple sclerosis patients with fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Membranes, myelin, and the pathophysiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Evolving expectations around early management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Benign multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6678-0

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

21 January 2018

1 reference

12 December 2020

Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study

1 reference

12 December 2020

Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance

1 reference

12 December 2020

Memory Rehabilitation for people with multiple sclerosis

1 reference

12 December 2020

Working memory training in patients with multiple sclerosis - comparison of two different training schedules.

1 reference

12 December 2020

A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis.

1 reference

12 December 2020

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

1 reference

12 December 2020

The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study

1 reference

12 December 2020

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

1 reference

12 December 2020

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

1 reference

12 December 2020

Cognitive training in MS: effects and relation to brain atrophy.

1 reference

12 December 2020

Effects of rivastigmine on memory and cognition in multiple sclerosis.

1 reference

12 December 2020

Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales

1 reference

12 December 2020

Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).

1 reference

12 December 2020

Teaching memory strategies to persons with multiple sclerosis.

1 reference

12 December 2020

10.1007/S00415-012-6678-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1040760338

0 references

1 reference